Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14770861 | 0.90 | MDM2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL13495919 | 0.90 | KMT2A (0.61) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL15305865 | 0.90 | KMT2A (0.50) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL14147622 | 0.90 | MDM2 (0.57) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL17919592 | 0.90 | KMT2A (0.61) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL19130178 | 0.90 | KMT2A (0.50) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL30265401 | 0.89 | KMT2A (0.53) | TLR2KMT2AMDM2PTPN1 | |
| SCHEMBL18474877 | 0.89 | KMT2A (0.49) | TLR2KMT2AMDM2MDM4TP53 | |
| Hydrochloric Acid SCHEMBL30744256 | 0.89 | MDM2 (0.56) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL13452073 | 0.88 | TLR2 (0.58) | TLR2KMT2AMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197891-A1 | METHOD FOR PEPTIDE SYNTHESIS | LONZA AG (CH) | 2010-08-05 | — | — | US | disclosed |
| WO-2008040536-A1 | METHOD FOR PEPTIDE SYNTHESIS | LONZA AG (CH) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197891-A1 | METHOD FOR PEPTIDE SYNTHESIS | DNPEP, NGLY1, PTMS | TLR2 4602/4885KMT2A 3121/4885MDM2 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.